十一月 2025
- Home
- Adamas Pharmaceuticals
十一月 2025的Adamas Pharmaceuticals市场份额分析
Adamas Pharmaceuticals(包含公司地区分支机构)
查看更多网站流量和参与度信息- adamaspharma.com
Adamas Pharmaceuticals收入截至 十一月 2025为 50M - 75M
Adamas Pharmaceuticals主要域名产生的收入
3 年中Adamas Pharmaceuticals主要域名的收入
Adamas Pharmaceuticals主要域名的收入
Adamas Pharmaceuticals热门域名的总访问量
了解Adamas Pharmaceuticals市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
无数据可显示
无数据可显示
Adamas Pharmaceuticals热门域名的平均访问时长
分析Adamas Pharmaceuticals参与度指标。
过去 3 个月的平均访问时长
无数据可显示
无数据可显示
Adamas Pharmaceuticals热门域名的平均页面浏览量
了解Adamas Pharmaceuticals如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
无数据可显示
无数据可显示
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Adamas Pharmaceuticals 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻The Company acquired Adamaspharma on Nov 1st '21.(1) The Company acquired Adamas Pharmaceuticals, Inc. in November 2021 (the "Adamas Acquisition").
十一月 8, 2022阅读更多
新闻Quartel left Adamaspharma as Chief Medical Officer overseeing research and development on Jan 1st '20.Dr. Quartel joins Acer from Adamas Pharmaceuticals where he served as Chief Medical Officer overseeing research and development, as well as medical affairs and regulatory functions.
五月 16, 2022阅读更多
新闻Adamaspharma has issues with violated the federal securities laws.Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors of its investigation into whether the officers or directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN).
十月 25, 2021阅读更多
查看 Adamas Pharmaceuticals 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。